


PCT/US 97/01978

09/09/165  
5

6 CODE LABEL 		U.S. PATENT APPLICATION			
SERIAL NUMBER 60/012,111 PROVISIONAL		FILING DATE 02/06/96		CLASS	GROUP ART UNIT
APPLICANT	ANNE R. MILLER, INDIANAPOLIS, IN.				REC'D 03 APR 1997
	**CONTINUING DATA***** VERIFIED				WIPO PCT
**FOREIGN/PCT APPLICATIONS***** VERIFIED					
FOREIGN FILING LICENSZ GRANTED 04/15/96					
STATE OR COUNTRY IN	SHEETS DRAWING 0	TOTAL CLAIMS	INDEPENDENT CLAIMS	FILING FEE RECEIVED \$150.00	ATTORNEY DOCKET NO. P-9872
ADDRESS	ELI LILLY AND COMPANY PATENT DIVISION DC 1104 LILLY CORPORATE CENTER INDIANAPOLIS IN 46285				
TITLE	DIABETES THERAPY				
This is to certify that annexed hereto is a true copy from the records of the United States Patent and Trademark Office of the application which is identified above. By authority of the COMMISSIONER OF PATENTS AND TRADEMARKS Date FEB 26 1997 Certifying Officer <i>B. Bleed</i>					

60012111

PATENT APPLICATION SERIAL NO. \_\_\_\_\_

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FEE RECORD SHEET

PTO-1556  
(5/87)

60012111

60012111

60012111

60012111

60012111

60012111

60012111

60012111

60012111

60012111

60012111

60012111

30012111



DIABETES THERAPY

Technical Field of Invention

The present invention relates to genetic engineering as applied to pharmaceutical research and development in the general area of gene therapy. In particular, this invention relates to the use of stable, transformed human cell lines as vehicles for transferring functional human genes useful in the treatment of diabetes mellitus.

Background of the Invention


Endocrine secretions of pancreatic islets are regulated by complex control mechanisms driven not only by blood-borne metabolites such as glucose, amino acids, and catecholamines, but also by local paracrine influences. The major pancreatic islet hormones, glucagon, insulin and somatostatin, interact with specific pancreatic cell types (A, B, and D cells, respectively) to modulate the secretory response. Although insulin secretion is predominantly controlled by blood glucose levels, somatostatin inhibits glucose-mediated insulin secretion. In addition to inter-islet paracrine regulation of insulin secretion, there is evidence to support the existence of insulinotropic factors in the intestine. This concept originates from observations

"Express Mail" mailing label number TB810319609US

Date of Deposit February 6, 1996

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Ronald S. Maciak  
Printed Name

  
Signature

that glucose taken orally is a much more potent stimulant of insulin secretion than is a comparable amount of glucose given intravenously.

The human hormone glucagon is a 29-amino acid hormone produced in pancreatic A-cells. The hormone belongs to a multi-gene family of structurally related peptides that include secretin, gastric inhibitory peptide, vasoactive intestinal peptide and glicentin. These peptides variously regulate carbohydrate metabolism, gastrointestinal mobility and secretory processing. However, the principal recognized actions of pancreatic glucagon are to promote hepatic glycogenolysis and gluconeogenesis, resulting in an elevation of blood sugar levels. In this regard, the actions of glucagon are counter regulatory to those of insulin and may contribute to the hyperglycemia that accompanies diabetes mellitus (Lund, P.K., et al., *Proc. Natl. Acad. Sci. U.S.A.*, 79:345-349 (1982)).

When glucagon binds to its receptor on insulin producing cells, cAMP production increases which in turn stimulates insulin expression (Korman, L.Y., et al., *Diabetes*, 34:717-722 (1985)). Moreover, high levels of insulin down-regulate glucagon synthesis by a feedback inhibition mechanism (Ganong, W.F., *Review of Medical Physiology*, Lange Publications, Los Altos, California, p. 273 (1979)). Thus, the expression of glucagon is carefully regulated by insulin, and ultimately by serum glucose levels.

P-proglucagon, the precursor form of glucagon, is encoded by a 360 base pair gene and is processed to form proglucagon (Lund, et al., *Proc. Natl. Acad. Sci. U.S.A.*, 79:345-349 (1982)). Patzelt, et al. (*Nature*, 282:260-266 (1979)), demonstrated that proglucagon is further processed into glucagon and a second peptide. Later experiments demonstrated that proglucagon is cleaved carboxyl to Lys-Arg or Arg-Arg residues (Lund, P.K., et al., Lopez L.C., et al., *Proc. Natl. Acad. Sci. U.S.A.*, 80:5485-5489 (1983), and Bell, G.I., et al., *Nature* 302:716-718 (1983)). Bell, G.I., et al., also discovered that proglucagon contained three

discrete and highly homologous peptide regions which were designated glucagon, glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2). Lopez, et al., demonstrated that GLP-1 was a 37 amino acid peptide and that GLP-2 was a 34 amino acid peptide. Analogous studies on the structure of rat preproglucagon revealed a similar pattern of proteolytic cleavage at Lys-Arg or Arg-Arg residues, resulting in the formation of glucagon, GLP-1, and GLP-2 (Heinrich, G., et al., *Endocrinol.*, 115:2176-2181 (1984)). Finally, human, rat, bovine, and hamster sequences of GLP-1 have been found to be identical (Ghigllione, M., et al., *Diabetologia*, 27:599-600 (1984)).

The conclusion reached by Lopez, et al., regarding the size of GLP-1 was confirmed by studying the molecular forms of GLP-1 found in the human pancreas (Uttenthal, L.O., et al. *J. Clin. Endocrinol. Metabol.*, 61:472-479 (1985)). Their research showed that GLP-1 and GLP-2 are present in the pancreas as 37 and 34 amino acid peptides respectively.

The similarity between GLP-1 and glucagon suggested to early investigators that GLP-1 might have biological activity. Although some investigators found that GLP-1 could induce rat brain cells to synthesize cAMP (Hoosein, N.M., et al., *Febs Lett.* 178:83-86 (1984)), other investigators failed to identify any physiological role for GLP-1 (Lopez, L.C., et al. *supra*). The failure to identify any physiological role for GLP-1 caused some investigators to question whether GLP-1 was in fact a hormone and whether the relatedness between glucagon and GLP-1 might be artifactual.

It has now been shown that biologically processed forms of GLP-1 have insulinotropic properties and delay gastric emptying. GLP-1(7-34) and GLP-1(7-35) are disclosed in U.S. Patent No: 5,118,666, herein incorporated by reference. GLP-1(7-37) is disclosed in U.S. Patent No: 5,120,712, herein incorporated by reference.

Variants and analogs of GLP-1 are known in the art. These variants and analogs include, for example, GLP-1(7-36), Glu<sup>1</sup>-GLP-1(7-37), Thr<sup>1</sup>-Lys<sup>1</sup>-GLP-1(7-37), and Lys<sup>1</sup>-

GLP-1(7-37). Derivatives of GLP-1 include, for example, acid addition salts, carboxylate salts, lower alkyl esters, and amides (see, e.g., WO91/11457). Generally, the various disclosed forms of GLP-1 are known to stimulate insulin  
5 secretion (insulinotropic action) and cAMP formation (see, e.g., Mojsov, S., *Int. J. Peptide Protein Research*, 40:333-343 (1992)).

More importantly, numerous investigators have demonstrated a predictable relationship between various in  
10 vitro laboratory experiments and mammalian, especially human, insulinotropic responses to exogenous administration of GLP-1, GLP-1(7-36) amide, and GLP-1(7-37) acid (see, e.g., Nauck, M.A., et al., *Diabetologia*, 36:741-744 (1993); Gutniak, M., et al., *New England J. of Medicine*, 326(20):1316-1322 (1992);  
15 Nauck, M.A., et al., *J. Clin. Invest.*, 91:301-307 (1993); and Thorens, B., et al., *Diabetes*, 42:1219-1225 (1993)).

The fundamental defects responsible for causing hyperglycemia in mature onset diabetes include impaired secretion of endogenous insulin and resistance to the effects  
20 of insulin by muscle and liver tissue (Galloway, J.S., *Diabetes Care*, 13:1209-1239, (1990)). The latter defect results in excess glucose production in the liver. Thus, whereas a normal individual releases glucose at the rate of approximately 2 mg/kg/minute, a patient with mature onset  
25 diabetes releases glucose at a rate exceeding 2.5 mg/kg/minute, resulting in a net excess of at least 70 grams of glucose per 24 hours.

Because there exists exceedingly high correlations between hepatic glucose production, fasting blood glucose  
30 levels, and overall metabolic control as indicated by glycohemoglobin measurements (Galloway, J.A., *supra*; and Galloway, J.A., et al., *Clin. Therap.*, 12:460-472 (1990)), it is readily apparent that control of fasting blood glucose is essential for achieving overall normalization of metabolism  
35 sufficient to prevent hyperglycemic complications. Since existing insulin therapies rarely normalize hepatic glucose production without producing significant hyperinsulinemia and

hypoglycemia (Galloway, J.A., and Galloway, J.A., et al., supra) alternative approaches for diabetic therapy are needed.

Therapy based on administration of longer acting GLP-1 analogs is one such approach. To date however, this approach has failed to deliver long term efficacious doses to individuals due in large part because the serum half-life of GLP-1(7-37)-based peptides is quite short. Therefore, the quest for alternative approaches continues.

Gene therapy offers a new avenue for treating diseases rooted in hormone deficiencies because it operates as an *in vivo* protein production and delivery system. This is an especially attractive approach since gene therapy also offers the possibility of physiologically regulating the production and secretion of proteins in response to homeostatic mediators within the body.

Gene therapy can be effected in a number of ways. Retroviral-mediated gene transfer was suggested for treating human diseases involving malfunctioning bone marrow. Anderson et al., *Science* 226: 401 (1984). In addition, PCT Publication Number WO93/09222 (May 13, 1993) and U.S. Patent Number 5,399,346 (March 21, 1995) disclose the genetic alteration of primary human cells that are cultured then reintroduced into the body for the treatment of a variety of diseases.

Accordingly, the primary object of this invention is to provide a means for stimulating the expression and secretion of insulin and/or for delaying gastric emptying which results in lowering elevated serum glucose levels in individuals suffering from diabetes.

#### Summary of the Invention

A stable human cell line transformed with an expression vector comprising a DNA sequence encoding a protein of Formula I is claimed. The invention also includes a method of treating Type I or Type II diabetes in a patient



in need thereof comprising implanting the genetically engineered cells, which secrete a protein of Formula 1, into the patient.

#### Detailed Description of the Invention

5           Many heritable diseases such as diabetes result from the absence of a functional gene necessary to provide the animal with an adequate supply of a vital protein. Gene therapy functions to supply a functional gene encoding the protein using recombinant DNA or RNA vectors. Although there  
10 are a number of possible methods used to incorporate the desired DNA into the target cells, there are two general procedures employed termed ex vivo and in vivo therapy for introducing the gene therapy nucleotide sequence into the afflicted individual.

15           Ex vivo therapy consists of four primary steps:  
(1) Primary cells (target cells) are removed from the individual in need of therapy; (2) The gene therapy nucleotide sequence is incorporated into the target cell in vitro; (3) Transformed cells expressing the protein of  
20 interest are identified, isolated, and expanded; and (4) The transformed cells are reintroduced into the individual. Ex vivo therapy generally results in the incorporation of the nucleotide sequence encoding the protein of interest into the chromosomal DNA of the target cell. The critical step of ex vivo gene therapy is the proper introduction of the  
25 nucleotide sequence encoding the desired protein into the target cell. The introduction of the desired gene is generally accomplished by the use of viral vectors, although other methods are also applicable. Two primary types of viral vectors are frequently used for the introduction of the foreign gene into the target cell: (1) retroviral vectors and (2) adeno-associated viruses (AAVs). The choice of an appropriate retroviral vector is dependent on the existence of an appropriate viral receptor on the target cell. A variety of retroviral vectors appropriate for the

transduction of a variety of cell lines have been described in the literature. The use of retroviral vectors is generally accomplished by the use of "packaging cells" which permit the production of high titers of replication-defective recombinant virus free of wild-type virus. Miller, *Human Gene Therapy*, vol. 1, number 5 (1990). Adeno-associated viruses (AAVs) may also be used to efficiently transfer genes in vitro. Production of high titers of replication-defective recombinant virus has been described. Flotte et al. *Gene Therapy* 2:29 (1995); *Current Topics in Microbiol. Immunol.* 158:92 (1992); Kotin *PNAS (USA)* 87:2211 (1990).

In vivo gene therapy generally describes the introduction of a nucleotide sequence into an individual in need of therapy without first isolating primary cells and manipulating them in vitro. In vivo therapy generally results in foreign nucleotide sequences being transferred to the nucleus of cells of an animal without subsequent integration into the genome. Adenoviral vectors are frequently used to deliver DNA into the cells because these viruses are capable of infecting non-dividing cells and expressing foreign genes. Replication defective adenoviruses lacking portions of the E1 region of the viral genome can be propagated by growth in cells engineered to express the E1 genes. Shenk, *Cell* 16:683 (1979). Subsequent studies have indicated that replication defective adenoviruses carrying foreign DNA sequences could infect non dividing cells. Once inside the cells, the foreign DNA has been shown to express active protein. Becker et al., "Protein Expression in Animal Cells" *Methods of Enzymology* (1995).

The present invention provides a method of treating both Type I and Type II diabetics through a gene therapy approach to allow the body to produce a GLP-1(7-37)-based protein. The expressed GLP-1(7-37)-based protein, in conjunction with high serum glucose levels, causes pancreatic beta cells to produce insulin in non-insulin dependent diabetes mellitus (NIDDM) patients and delays gastric emptying in both NIDDM and insulin dependent diabetes

mellicus IDDM patients. The instant invention provides gene therapy methods and constructions allowing for the in vivo production of a GLP-1(7-37)-based compound of the Formula 1:

5 His-Xaa<sup>1</sup>-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-  
Leu-Xaa<sup>2</sup>-Gly-Gln-Ala-Ala-Xaa<sup>3</sup>-Xaa<sup>4</sup>-Phe-Ile-Ala-Trp-Leu-  
Val-Lys-Gly-Arg-Xaa<sup>5</sup>

wherein

Xaa<sup>1</sup> is Ala, Gly, Val, Thr, and Ile; preferably Ala;

Xaa<sup>2</sup> is Glu, Gln, Ala, Thr, Ser, and Gly; preferably

10 Glu;

Xaa<sup>3</sup> is Lys and Arg; preferably Lys;

Xaa<sup>4</sup> is Glu, Gln, Ala, Thr, Ser, and Gly; preferably

Glu and ,

Xaa<sup>5</sup> is Gly-OH or is absent; preferably Gly-OH.

15

Nucleotide sequences encoding any one of the compounds of Formula 1 may be prepared by a variety of means readily apparent to those skilled in the art. Wholly synthetic nucleotide sequences or semi-synthetic sequences  
20 derived in part from a natural GLP-1 gene may be used. Owing to the natural degeneracy of the genetic code, the skilled artisan will recognize that a sizable yet definite number of nucleotide sequences may be constructed which encode the compounds of the Formula 1. A synthetic DNA sequence  
25 encoding a GLP-1-based protein of Formula 1 may be prepared by techniques well known in the art in substantial accordance with the teachings of Brown, et al. (1979) *Methods in Enzymology*, Academic Press, N.Y., Vol. 68, pgs. 109-151. The DNA sequence may be generated using conventional DNA  
30 synthesizing apparatus such as an Applied Biosystems Model 380A or 380B DNA synthesizer (commercially available from Applied Biosystems, Foster City, California). Commercial services are also available for the construction of such nucleotide sequences based on the amino acid sequence.

In the preferred practice of the invention as exemplified herein a preferred synthetic coding region is assembled comprising a DNA sequence encoding a compound of the Formula 1 having the DNA sequence:

5    5' - CAT GCT GAA GGG ACC TTT ACC AGT GAT GTA AGT TCT TAT TTG  
          GAA GGC CAA GCT GCC AAG GAA TTC ATT GCT TGG CTG GTG AAA  
          GGC CGA GGA - 3'

Coding regions for Formula 1 are preferably fused to a leader sequence which signals the cell to secrete a precursor peptide of Formula 1 that is subsequently processed by the cell to a protein of Formula 1. Many such leader sequences are known in the art. One well known preferred leader sequence is the hybrid tissue plasminogen activator:protein C prepropeptide described in Berg et al. 15    *Biochem. Biophys. Res. Commun.* 179: 1289-1296 (1991). Typically nucleotide sequences encoding precursor peptides of Formula 1 are flanked by linker DNA to facilitate enzymatic ligation into expression vectors.

Once a suitable coding sequence of Formula 1 is constructed and optionally fused and flanked by an appropriate leader sequence and linker DNA, the construct is integrated into an expression vector then transfected into an appropriate target cell. In gene therapy, there are alternative means for introducing the genetic information 25    necessary into a target cell.

The use of retroviral vectors allows efficient introduction of genetic information into large numbers of cells. Retroviral vectors, especially those derived from the Moloney murine leukemia virus (M-MLV), are particularly useful in the integration of foreign genetic material into the host chromosome. In the construction of such vectors, the nucleotide sequence encoding the desired compound of Formula 1 is inserted with its control region into the region of the retroviral structural gene region of the retrovirus (e.g., the gag, pol, and env genes).

Retroviral regulatory elements (enhancer and promoters) are capable of conducting efficient expression of the transduced genes in a wide variety of target cell types. However, additional regulatory sequences may be added to achieve tissue specific expression by the use of tissue specific enhancer and promoter elements.

Alternatively adenoviral vectors may be employed. Jones and Shenk (1979) Cell 16:683, demonstrated that replication deficient adenoviruses containing deletions of the E1 region of the viral genome could be propagated in cells engineered to express the E1 genes. Typical constructions of adenoviral gene therapy vectors are constructed by insertion of the foreign DNA into the E1A-E1B and E3 regions of the viral genome. Expression of the foreign DNA sequence is generally under control of the E1A promoter, the major late promoter (MLP) and associated sequences, the E3 promoter.

Other viral vectors are known for their utility in the introduction of foreign nucleotide sequences for gene therapy applications. For example, derivatives of adeno-associated virus (AAV), herpes virus and vaccinia virus vectors have been demonstrated to have utility in gene therapy.

As an alternative to viral introduction, it is possible to use receptor-mediated methods of gene transfer. In such instances, a complex is formed between the target tissue receptor and the plasmid DNA and polypeptides and the receptor on the cell surface. The plasmid DNA is taken up by the cell in endocytotic mediated transfer. The plasmid DNA may then be released from the vesicle after incorporation into the cell. Other techniques known in the art for incorporating plasmid DNA directly into target tissue rely on lipid-CaPO<sub>4</sub> methodologies. See Wang et al., J. Clin. Investig. 95 1710-1716 (1995); Ma et al., J. Biol. Chem. 270 491-495 (1995).

Construction of suitable vectors containing the desired coding and control sequences may be constructed by

standard ligation techniques. Isolated plasmids or nucleotide fragments are cleaved, tailored, and religated in the manner necessary to achieve the desired plasmids. To effect the expression of a compounds of Formula 1, one  
5 inserts a nucleotide sequence encoding the compound into an appropriate recombinant nucleotide expression vector through the use of appropriate restriction endonucleases. The nucleotide sequence encoding a compound of Formula 1 is designed to possess restriction endonuclease cleavage sites  
10 at either end of the DNA to facilitate isolation from and integration into these amplification and expression plasmids. The coding sequence may be readily modified by the use of synthetic linkers to facilitate the incorporation of the coding sequence into the desired cloning vectors by  
15 techniques well known in the art. The particular endonucleases employed will be dictated by the restriction endonuclease cleavage pattern of the parent expression vector to be employed. The choice of restriction sites are chosen so as to properly orient the coding sequence such that it is  
20 properly associated with the promoter and ribosome binding site of the expression vector, both of which are functional in the host cell in which a compound of Formula 1 is to be expressed.

In general, plasmid vectors containing promoters  
25 and control sequences which are derived from species compatible with the host cell are used. The vector ordinarily carries a replication site as well as marker sequences which are capable of providing phenotypic selection in transformed cells.

Because the compounds of the present invention do  
30 not require post-translational processing mechanisms other than enzymatic removal of the propeptide leader sequence, many stable human cell lines may be used. One preferred cell line is the human embryonal kidney cell line 293, available  
35 from the permanent collection of the American Type Culture Collection. The techniques of transforming mammalian cells with the aforementioned vector types are well known in the

art and may be found in such general references as Maniatis,  
et al. (1989) Molecular Cloning: A Laboratory Manual, Cold  
Spring Harbor Press, Cold Spring Harbor Laboratory, Cold  
Spring Harbor, New York or Current Protocols in Molecular  
5 Biology, Vol. 1, (1988), Wiley Interscience, and  
supplements.

Stable transformed cell lines that express  
proteins of Formula 1 must then be implanted into individuals  
in need thereof. The site of implantation should be  
10 compatible with the origin of the cell line used. For  
example, the human embryonal kidney cell line, once  
transformed to constitutively produce proteins of Formula 1  
are preferably transplanted under the renal capsule.

Because such cell lines generally will be  
15 histologically incompatible with the individuals receiving  
them, the cells are preferably masked with F(ab')<sub>2</sub> fragments  
specific for HLA class I antigens. Such immunological  
masking methods are known in the art as described by Faust et  
al. *Science* 252:1700-1702 (1991). Other means for isolating  
20 the transformed cells from the recipient's immune system are  
consistent with this invention. Such methods include but are  
not limited to encasulation in semi-permeable membranes.

By way of illustration, the following examples are  
provided to help describe how to make and practice the  
25 various embodiments of the invention. These example are in  
no way meant to limit the scope of the invention.

#### Example 1

##### Construction of Intermediate

##### Plasmid pLP53-tLB+GLP-1

##### 30 A. Preparation of BglII-Mung Bean-AvrII Digested pLP53-tLB

The plasmid pLP53-tLB was isolated from  
Escherichia coli K12 AG1 (on deposit under terms of the  
Budapest Treaty and made part of the permanent stock culture  
collection of the the Northern Regional Research Center,

agricultural Research Service, U.S. Dept. of Agriculture, Peoria, IL 61604 under accession number NRRL B-18714) using the Plasmid Purification Midi Kit obtained from Qiagen, Inc. (9600 DeSoto Avenue, Chatsworth, CA 91311).

5           Sixty  $\mu$ l (20  $\mu$ g) of pLP53-tLB DNA was digested with 2  $\mu$ l (20 units) of BglII in a 70  $\mu$ l reaction volume containing 50mM Tris-HCl (pH 8.0), 10mM MgCl<sub>2</sub>, and 100mM NaCl. The sample was incubated at 37°C for one hour. 17.5  $\mu$ l of 5x stop mix (25% glycerol, 2% SDS, 0.05% bromophenol  
10 blue, 0.05% xylene cyanol) was added and then the reaction was heated at 70°C for 15-20 minutes to inactivate the restriction enzyme. The mixture was spin dialyzed using G-50 Sephadex Quick Spin columns obtained from Boehringer Mannheim Corporation (P.O. Box 50414, 9115 Hague Road, Indianapolis,  
15 IN 46250-0414) in order to remove the reaction components.

          The 5' protruding ends created by cleavage with BglII were removed using Mung Bean Nuclease. The BglII digested pLP53-tLB DNA was incubated with 0.3  $\mu$ l (3.3 units) of Mung Bean Nuclease in a 100  $\mu$ l reaction volume containing  
20 10mM Tris-HCl (pH 7.9 at 25°C), 10mM MgCl<sub>2</sub>, 50mM NaCl, 1mM DTT, and 1mM ZnSO<sub>4</sub>. The reaction was allowed to proceed for 30 minutes at 30°C. One  $\mu$ l of 1% SDS was added to inactivate the nuclease. Due to an incomplete BglII digest, the digested and undigested DNA was separated by gel  
25 electrophoresis. Ten  $\mu$ l of gel loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 30% glycerol in water) was added to the reaction. The reaction was loaded into the preparative well of a 1.5% NuSieve GTG agarose (FMC BioProducts, 191 Thomaston Street, Rockland, ME 04841)/TAE  
30 buffer gel and then electrophoresed. The gel was stained with ethidium bromide and then the DNA was visualized by ultraviolet light. The digested DNA band was excised with a scalpel and placed into two micro-tubes. The DNA was purified from the low melting point agarose using the Wizard  
35 PCR Preps DNA Purification System obtained from Promega (2800 Woods Hollow Road, Madison, WI 53711-5399).



One hundred  $\mu$ l of BglII-Mung Bean digested pLP53-tLB DNA was further digested with 4  $\mu$ l (16 units) of AvrII in a reaction volume of 120  $\mu$ l containing 10mM Tris-HCl (pH 7.9 at 25°C), 10mM MgCl<sub>2</sub>, 50mM NaCl, 1mM DTT. The sample was

5 incubated at 37°C for 30 minutes. To prevent recircularization, the BglII-Mung Bean-AvrII digested pLP53-tLB DNA was dephosphorylated (removal of 5' phosphate groups) by the addition of 2  $\mu$ l (2 units) of calf intestinal alkaline phosphatase to the reaction. The sample was incubated at

10 37°C for an additional 30 minutes. Twenty-four  $\mu$ l of 5x stop mix was added. The sample was heated at 70°C for 15-20 minutes to inactivate the enzymes and then spin dialyzed using G-50 Sephadex Quick Spin columns obtained from

15 Boehringer Mannheim Corporation (P.O. Box 50414, 9115 Hague Road, Indianapolis, IN 46250-0414) in order to remove the AvrII produced small DNA fragments. The DNA was precipitated by addition of 0.1 volume of 3M sodium acetate (pH 5.2) and 2.5 volumes of absolute ethanol. This mixture was mixed thoroughly and then chilled at -20°C. The precipitate was

20 collected by centrifugation for 30 minutes. The supernatant was discarded and the pellet was washed with 700  $\mu$ l of cold 70% ethanol. The sample was centrifuged for 15 minutes. The supernatant was discarded, the DNA pellet was dried and then resuspended in 25  $\mu$ l of water.

25 B. Preparation of GLP-1 Linker

The following single stranded DNA segments were conventionally synthesized by methods well known in the art on an automated DNA synthesizer (model 394 Applied Biosystems 250 Lincoln Center Drive, Foster City, CA 94404-1128) using

30 2'-cyanoethyl phosphoramidite chemistry.

GLP-1.1

5' - GACATGCTGA AGGGACCTTT ACCAGTGATG TAAGTTCTTA TTTGGAAGGC  
TAAGTGTCCA AGGAATTCAT TGCTTGGCTG GTGAAAGGCC GAGGATAGGG ATCCC

3' -

GLP-1.2

5' - CTAGGGGATC CCTATCCTCG GCCTTTCACC AGCCAAGCAA TGAATTCCTT  
GGCAGCTTGG CCTTCCAAAT AAGAACTTAC ATCACTGGTA AAGGTCCTT  
CAGCATGTC - 3'

5 GLP-1.1 and GLP-1.2 are complementary DNA molecules. The synthetic DNA molecules were dissolved in water and stored at less than 0°C.

To anneal the DNA strands, 92.7 pmoles each of  
10 GLP-1.1 and GLP-1.2 were mixed in 50mM Tris-HCl (pH 7.4) and 10mM MgCl<sub>2</sub> in a total volume of 80 µl and boiled for 5 minutes. The mixture was slowly brought to room temperature and then transferred to 4°C overnight. This process allowed the two complementary strands to anneal and form the  
15 double stranded DNA linker known as GLP-1. The linker was stored at -20°C. In order to be able to ligate into the dephosphorylated BglIII-Mung Bean-AvrII digested pLP53-tLB DNA segment, the GLP-1 linker must have 5' phosphate groups. The phosphate groups were added by the use of the enzyme T4  
20 polynucleotide kinase. The kinase reaction contained 80 µl of the GLP-1 linker, 0.33µM ATP, 70mM Tris-HCl (pH 7.6), 10mM MgCl<sub>2</sub>, 100mM KCl, 1mM β-mercaptoethanol and 37.2 µl (372 units) of T4 polynucleotide kinase. The reaction was incubated at 37°C for 30 minutes. Sixteen µl of 500mM EDTA  
25 was added to stop the reaction. The reaction was extracted once with a mixture of phenol:chloroform:isoamyl alcohol 25:24:1 followed by an extraction with chloroform:isoamyl alcohol (24:1). One hundred µl of the aqueous layer was spin dialyzed using G-50 Sephadex Quick Spin columns obtained from  
30 Boehringer Mannheim Corporation (P.O. Box 50414, 9115 Hague Road, Indianapolis, IN 46250-0414) in order to remove the reaction components. The DNA was precipitated by addition of 0.1 volume of 3M sodium acetate (pH 5.2), 0.1 volume of 100mM MgCl<sub>2</sub> and 2.5 volumes of absolute ethanol. This mixture was  
35 mixed thoroughly and then chilled at -20°C. The precipitate was collected by centrifugation for 30 minutes. The supernatant was discarded and the pellet was washed with 700

μl of cold 70% ethanol. The sample was centrifuged for 15 minutes. The supernatant was discarded, the DNA pellet was dried and then resuspended in 10 μl of water.

5 C. Final Construction of pLP53-tLB+GLP-1

The DNA prepared in Example 1A was ligated with linker GLP-1. Two μl of DNA prepared in Example 1A and 4 μl of GLP-1 linker were ligated in a reaction that contained 2 μl (2 units) of T4 DNA ligase, 50mM Tris-HCl (pH 7.6), 10mM  
10 MgCl<sub>2</sub>, 1mM ATP, 1mM DTT, and 50% (w/v) polyethylene glycol-8000 in a total volume of 10 μl. The mixture was incubated at 16°C for 16 hours. The ligation was used to transform Escherichia coli K12 INVaF' cells as generally described below.

15

D. Transformation Procedure

Frozen competent Escherichia coli K12 INVaF' cells are obtained from Invitrogen (3985 B Sorrento Valley Boulevard, San Diego, CA 92121). Two μl of 0.5M β-  
20 mercaptoethanol is added to 50 μl of thawed competent cells. About 1-2 μl of the ligation reaction is mixed with the cells. The cell-DNA mixture is incubated on ice for 30 minutes, heat-shocked at 42°C for exactly 30 seconds and then chilled on ice for 2 minutes. The cell-DNA mixture is  
25 diluted into 450μl of SOC media (2% tryptone, 0.05% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl<sub>2</sub>, 10mM MgSO<sub>4</sub>, 20mM glucose in distilled water) and incubated at 37°C for one hour in a rotary shaker set at about 225 rpm. Aliquots of  
upto 200 μl are plated on TY-agar plates (1% tryptone, 0.5%  
30 yeast extract, 1% NaCl, and 1.5% agar, pH 7.4) containing 100μg/ml ampicillin and then incubated at 37°C until colonies appear.

E. DNA Isolation

35

Following transformation, ampicillin resistant cells were picked and inoculated into 3 ml of TY broth (1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.4) containing

100µg/ml ampicillin. These cultures were grown for about 16 hours at 37°C with aeration. Plasmid DNA was isolated from cultures using Wizard Minipreps obtained from Promega (2800 Woods Hollow Road, Madison, WI 53711-5399).

- 5           To obtain larger amounts of pLP53-tLB+GLP-1 plasmid DNA, large scale isolation was performed using the Plasmid Purification Midi Kit obtained from Qiagen, Inc. (9600 DeSoto Avenue, Chatsworth, CA 91311).

Example 2

10           Construction of pGT-h+tLB+GLP-1

A.   Preparation of BclI Digested pGT-h

- The plasmid pGT-h was isolated from Escherichia coli K12 GM48 (on deposit under terms of the Budapest Treaty and made part of the permanent stock culture collection of the Northern Regional Research Center, agricultural Research Service, U.S. Dept. of Agriculture, Peoria, IL 61604 under accession number NRRL B-18592) using the Plasmid Purification Midi Kit obtained from Qiagen, Inc. (9600 DeSoto Avenue, Chatsworth, CA 91311).

- 20           Ten µg (37.5 µl) of pGT-h DNA was digested to completion with 2 µl (20 units) of BclI in a 45 µl reaction volume containing 50mM Tris-HCl (pH 8.0), 10mM MgCl<sub>2</sub>, 50mM NaCl. The sample was incubated at 50°C for 1 hour. Eleven µl of 5x stop mix was added to the reaction mixture. The mixture was heated at 70°C for 15-20 minutes to inactivate the restriction enzyme and then spin dialyzed using G-50 Sephadex Quick Spin columns obtained from Boehringer Mannheim Corporation (P.O. Box 50414, 9115 Hague Road, Indianapolis, IN 46250-0414) in order to remove the reaction components.
- 30           The DNA was precipitated by adding 0.1 volume of 3M sodium acetate (pH 5.2) and 2.5 volumes of absolute ethanol. This mixture was mixed thoroughly and then chilled at -20°C. The precipitate was collected by centrifugation for 30 minutes. The supernatant was discarded and the pellet was washed with

700  $\mu$ l of cold 70% ethanol. The sample was centrifuged for 15 minutes. The supernatant was discarded, the DNA pellet was dried and then resuspended in 20  $\mu$ l of water.

Calf intestinal alkaline phosphatase was used to  
5 remove the 5' phosphate groups from the DNA segment in order to prevent recircularization of the pGT-h. Ten  $\mu$ l of the BclI digested pGT-h DNA was treated with 1  $\mu$ l (1 unit) of calf intestinal alkaline phosphatase in a 15  $\mu$ l reaction containing 50mM Tris-HCl (pH 8.5 at 20°C) and 0.1mM EDTA.  
10 The reaction was allowed to proceed for 45 minutes at 37°C. The phosphatase was inactivated by the addition of 1 $\mu$ l of 500mM EDTA and then heating at 65°C for 10 minutes. The reaction volume was increased to 100 $\mu$ l with water and then extracted twice with phenol:chloroform:isoamyl alcohol  
15 (25:24:1) followed by extraction with chloroform: isoamyl alcohol (24:1). The DNA was recovered from the aqueous layer by the addition of 0.1 volumes of 3M sodium acetate (pH 5.2) and 2.5 volumes of absolute ethanol. The mixture was mixed thoroughly and then chilled at -20°C. The precipitate was  
20 collected by centrifugation for 30 minutes. The supernatant was discarded and the pellet was washed with 700  $\mu$ l of cold 70% ethanol. The sample was centrifuged for 15 minutes. The supernatant was discarded, the DNA pellet was dried and then resuspended in 25  $\mu$ l of water.

125

#### B. Preparation of pLP53-tLB+GLP-1 BamHI Fragment

Thirty-five  $\mu$ l (10.6  $\mu$ g) of pLP53-tLB+GLP-1 DNA prepared in example 1 was digested with 0.5  $\mu$ l (25 units) of BamHI in a 40  $\mu$ l reaction volume containing 50mM Tris-HCl  
10 pH 8.0, 10mM MgCl<sub>2</sub>, and 100mM NaCl. The reaction was allowed to proceed at 37°C for one hour. Five  $\mu$ l of gel loading dye was added to the reaction. The reaction was loaded into the preparative well of a 4% NuSieve GTG agarose (FMC BioProducts, 191 Thomaston Street, Rockland, ME  
15 04841) /TAE buffer gel. The DNA was electrophoresed for about one hour at 70 constant volts. The gel was stained with ethidium bromide and then the DNA was visualized by

ultraviolet light. The desired 213 base pair DNA band was excised using a scalpel. The DNA was purified from the low melting point agarose using Wizard PCR preps obtained from Promega (2800 Woods Hollow Road, Madison, WI 53711-5399).

5

C. Final Construction of pGT-h+GLP-1

The DNA prepared in Example 2A was ligated with DNA prepared in Example 2B. One  $\mu$ l of DNA from Example 2A and 10.5  $\mu$ l of DNA from Example 2B were ligated in a reaction that contained 2  $\mu$ l (2 units) of T4 DNA ligase, 50mM Tris-HCl (pH 7.6), 10mM MgCl<sub>2</sub>, 1mM ATP, 1mM DTT, and 50% (w/v) polyethylene glycol-8000 in a total volume of 20  $\mu$ l. The mixture was incubated at 16°C for 16 hours. The ligation reaction was used to transform Escherichia coli K12 INVaF' as described in Example 1D. Plasmid DNA was isolated from ampicillin resistant cultures as described in Example 1E.

15

To obtain larger amounts of pGT-h+GLP-1 plasmid DNA for the purpose of transfection of mammalian cells, large scale isolation was performed using the alkaline lysis method. Plasmid DNA was transfected in human embryonal kidney cells using standard Calcium phosphate techniques such as those described by Wigler et al. P.N.A.S. USA 76 1373-1376 (1979).

20

Example 3

25

Implantation

The transformed 293 cell were cultured then surgically transplanted under the kidney capsule of 8 week old Zucker Diabetic Fatty (ZDF/Gmi<sup>TM</sup>-fa/fa) male rats. Under isoflurane anesthesia, a dorsal incision was made just posterior to the diaphragm, and using a rib spreader, the kidney was exposed. Approximately 20 million transformed 293 cells, in 200  $\mu$ l of Hank's buffer, were injected just under the kidney capsule using a 23 gauge blunt needle. The incision was sutured and protected from chewing with wound clips.

30

We Claim:

1. A stable human cell line transformed with an expression vector comprising a DNA sequence encoding a protein of the Formula:

5 His-Xaa<sup>1</sup>-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-  
Leu-Xaa<sup>2</sup>-Gly-Gln-Ala-Ala-Xaa<sup>3</sup>-Xaa<sup>4</sup>-Phe-Ile-Ala-Trp-Leu-  
Val-Lys-Gly-Arg-Xaa<sup>5</sup>

wherein

10 Xaa<sup>1</sup> is Ala, Gly, Val, Thr, and Ile;  
Xaa<sup>2</sup> is Glu, Gln, Ala, Thr, Ser, and Gly;  
Xaa<sup>3</sup> is Lys, and Arg;  
Xaa<sup>4</sup> is Glu, Gln, Ala, Thr, Ser, and Gly; and,  
Xaa<sup>5</sup> is Gly-OH or is absent; preferably Gly-OH.

2. The Cell line of **Claim 1** wherein the DNA  
15 sequence is

5' - CAT GCT GAA GGG ACC TTT ACC AGT GAT GTA AGT TCT TAT TTG  
GAA GGC CAA GCT GCC AAG GAA TTC ATT GCT TGG CTG GTG AAA  
GGC CGA GGA - 3'.

3. A method of treating Type I or Type II  
20 diabetes in a patient in need thereof comprising implanting  
the genetically engineered cells of **Claims 1 or 2** into the  
patient such that a protein of Formula 1 is secreted.

4. A method of treating Type I or Type II  
diabetes in a patient in need thereof comprising injecting an  
25 expression vector of **Claim 1** directly into the patient such  
that the expression vector is incorporated into the patient's  
cell and secretes a protein of Formula 1

5. A stable human cell line transformed with an  
expression vector capable of secreting a protein of Formula 1  
30 in response to high serum glucose levels substantially as  
hereinbefore described with reference to any one of the  
Examples.

Abstract of the Disclosure


The invention provides a gene therapy method for delivering safe and effective, long term amounts of glucagon-like insulintropic peptide capable of treating Type I and  
5 Type II diabetes. The invention eliminates the need for subcutaneous injections and is able to provide tight glucose control.





The  
Patent  
Office

US97/01978  
140  
The Patent Office  
Cardiff Road  
Newport  
Gwent  
NP9 1RH




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

7.2.1997


PRIORITY DOCUMENT



# Patents Form 1/77

Patents Act 1977  
(Rule 16)

The  
Patent  
Office



## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P-9872

2. Patent application number

(The Patent Office will fill in this part)

9603847.6

23 FEB 1996

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

ELI LILLY AND COMPANY,  
LILLY CORPORATE CENTER,  
INDIANAPOLIS,  
INDIANA 46285,  
UNITED STATES OF AMERICA

Patents ADP number (*if you know it*)

428904002

If the applicant is a corporate body, give the country/state of its incorporation

STATE OF INDIANA, UNITED STATES OF AMERICA

4. Title of the invention

DIABETES THERAPY

5. Name of your agent (*if you have one*)

K. G. TAPPING

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

LILLY INDUSTRIES LIMITED,  
ERL WOOD MANOR,  
WINDLESHAM,  
SURREY GU20 6PH

Patents ADP number (*if you know it*)

31286001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)

Date of filing  
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

YES

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	19
Claim(s)	1 <i>mw</i>
Abstract	1
Drawing(s)	-

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature



Date 20TH FEBRUARY 96

12. Name and daytime telephone number of person to contact in the United Kingdom

MR. K. G. TAPPING (01276) 853443

## Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*